Veeva Systems (NYSE:VEEV) Updates Q2 2026 Earnings Guidance

Veeva Systems (NYSE:VEEV) updated its second quarter 2026 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 1.890-1.900 for the period, compared to the consensus estimate of 1.880. The company issued revenue guidance of $766.0 million-$769.0 million, compared to the consensus revenue estimate of $765.3 million. Veeva Systems also updated its FY 2026 guidance to 7.630-7.630 EPS.

Veeva Systems Stock Down 1.1%

Shares of NYSE VEEV opened at $235.37 on Thursday. The stock’s 50 day moving average price is $228.89 and its two-hundred day moving average price is $227.27. Veeva Systems has a 52-week low of $170.25 and a 52-week high of $274.17. The stock has a market capitalization of $38.29 billion, a P/E ratio of 58.12, a PEG ratio of 1.89 and a beta of 0.96.

Veeva Systems (NYSE:VEEV) last issued its quarterly earnings results on Wednesday, May 28th. The technology company reported $1.97 earnings per share for the quarter, beating analysts’ consensus estimates of $1.74 by $0.23. Veeva Systems had a return on equity of 13.56% and a net margin of 25.07%. The business had revenue of $759.04 million during the quarter, compared to the consensus estimate of $728.38 million. During the same period in the previous year, the business earned $1.50 EPS. The business’s quarterly revenue was up 16.7% on a year-over-year basis. On average, analysts anticipate that Veeva Systems will post 4.35 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. Stephens restated an “overweight” rating and issued a $280.00 price target on shares of Veeva Systems in a research report on Thursday, March 6th. JPMorgan Chase & Co. increased their price objective on shares of Veeva Systems from $218.00 to $249.00 and gave the stock a “neutral” rating in a research note on Thursday, March 20th. Morgan Stanley lifted their target price on Veeva Systems from $195.00 to $201.00 and gave the company an “underweight” rating in a research note on Thursday, March 6th. Needham & Company LLC upped their target price on Veeva Systems from $270.00 to $300.00 and gave the company a “buy” rating in a report on Thursday. Finally, Robert W. Baird increased their price target on Veeva Systems from $283.00 to $285.00 and gave the stock an “outperform” rating in a research report on Thursday, March 6th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $256.12.

Insider Activity at Veeva Systems

In other Veeva Systems news, insider Thomas D. Schwenger sold 1,200 shares of the company’s stock in a transaction dated Monday, April 14th. The shares were sold at an average price of $220.97, for a total value of $265,164.00. Following the completion of the sale, the insider now directly owns 25,889 shares of the company’s stock, valued at approximately $5,720,692.33. This represents a 4.43% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Jonathan Faddis sold 787 shares of Veeva Systems stock in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $226.20, for a total transaction of $178,019.40. Following the completion of the transaction, the senior vice president now directly owns 8,668 shares in the company, valued at $1,960,701.60. This represents a 8.32% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 5,869 shares of company stock worth $1,284,917 over the last quarter. 10.30% of the stock is currently owned by company insiders.

About Veeva Systems

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.